

No.					
1	12-094-4			Aquala®	30 7 4
2	18-045				30 7 10
3	18-027				30 7 11
4	18-046				30 7 12
5	18-022-2				30 7 17
6	18-047			FOLFOX plus panitumumab RAS wild- type FOLFIRI plus panitumumab II Liquid Biopsy	30 7 17
7	18-048			EGFR II TORG1632	30 7 17
8	13-178-7			B/ CBDCA+TS-1 TS-1 (WJOG7512L)	30 7 18
9	18-052				30 7 19
10	18-053			1	30 7 19
11	18-054			+ II/III (TORG1630) A phase II/III study comparing nivolumab (NIV) with nivolumab (NIV) plus docetaxel (DTX) in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial (CONDUCT study) NIV vs NIV+DTX Phase II/ III (CONDUCT study/TORG1630)	30 7 19
12	18-055				30 7 19
13	17-060-2			-	30 7 20
14	18-026				30 7 24
15	18-028				30 7 25
16	18-057				30 7 25
17	18-058) (30 7 25
18	18-059				30 7 25
19	17-108-2				30 7 26
20	18-060				30 7 30